In situ Hybridization Market by Technique (FISH, CISH), Application (Cancer Diagnosis, Neuroscience, Cytology, Infectious Disease), & End User (Molecular Diagnostic Laboratories, Academic And Research Institutions) - Global Forecast to 2021

The in situ hybridization market is projected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). The growth of the overall market can be attributed to the increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, and increasing government initiatives globally.

In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.

North America is expected to account for the largest share of the global market. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents.

In the U.S., the in situ hybridization market is driven by increasing government initiatives, growing biomedical research, rising prevalence of cancer, and growing demand for companion diagnostics and personalized medicine.  In Canada, the growth of the market is driven by increased government funding and growing prevalence of cancer.

The report segments market based on technique, application, end user, and region.

On the basis of technique, the global market is segmented into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global in situ hybridization market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.

Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.

Stakeholders of the Global Market 

• Medical Device Manufacturers
• Diagnostic Laboratories
• Contract Research Organizations (CROs)
• Life Sciences Companies ( Pharmaceutical/Biotechnology)
• Academic Institutes
• Government and Private Research Institutes
• Regulatory Bodies
• Hospitals
• Market Research and Consulting Firms
• Venture Capitalists

To know about the assumptions considered for the study, download the pdf brochure

Scope of the Report:

This research report categorizes the global market into the following segments:

In situ Hybridization Market, by Technique

• Fluorescence In Situ Hybridization (FISH)
  • DNA-FISH
  • RNA-FISH
• Chromogenic In Situ Hybridization

In situ Hybridization Market, by Application

• Cancer Diagnosis
• Immunology
• Neuroscience
• Cytology
• Infectious Diseases

In situ Hybridization Market, by End User

• Molecular Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutions

In situ Hybridization Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • EU5
  • Rest of Europe (RoE)
• Asia-Pacific
• Rest of the World (RoW)

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization option is available for the report:

Portfolio Assessment

Product Matrix, which gives a detailed comparison of the product portfolios of the top three companies in the market.

Table of Contents

1 Introduction
    1.1 Objectives of the Study
    1.2 Market Definition
    1.3 Market Scope
           1.3.1  Markets Covered
           1.3.2  Years Considered for the Study
    1.4 Currency
    1.5 Limitations
    1.6 Stakeholders

2 Research Methodology
    2.1 Research Methodology Steps
    2.2 Secondary and Primary Research Methodology
           2.2.1  Secondary Research
           2.2.2  Primary Research
           2.2.3  Key Industry Insights
    2.3 Key Data From Primary Sources
    2.4 Key Insights From Primary Sources
    2.5 Market Size Estimation Methodology
           2.5.1  Research Design
    2.6 Market Data Validation and Triangulation
    2.7 Assumptions for the Study

3 Executive Summary

4 Market Overview
    4.1 Introduction
    4.2 Market Dynamics
           4.2.1  Drivers
           4.2.2  Restaints/Challenges
           4.2.3  Opportunities

5 By Technique
    5.1 Introduction
    5.2 Fluorescence In Situ Hybridization Market (FISH)
           5.2.1  DNA-FISH
           5.2.2  RNA-FISH
    5.3 Chromogenic In Situ Hybridization Market (CISH)

6 By Application
    6.1 Introduction
    6.2 Cancer Diagnosis
    6.3 Immunology
    6.4 Neuroscience
    6.5 Cytology
    6.6 Infectious Diseases

7 By End-User
    7.1 Introduction
    7.2 Molecular Diagnostic Laboratories
    7.3 Pharmaceutical & Biotechnology Companies
    7.4 Contract Research Organizations (CROS)
    7.5 Academic & Research Institutions

8 By Region
    8.1 Introduction
    8.2 North America
           8.2.1  U.S.
           8.2.2  Canada
    8.3 Europe
           8.3.1  EU5- (U.K, Germany, France, Spain & Italy)
           8.3.2  Rest of Europe (RoE)
    8.4 Asia-Pacific
    8.5 Rest of the World

(Consolidated Market Numbers for Latin America, Middle-East and Africa Will Be Provided)

9 Competitive Landscape
    9.1 Overview
    9.2 Competitive Situation and Trends
           9.2.1  Approvals
           9.2.2  Product Deployments
           9.2.3  New Product Launches
           9.2.4  Others (If Any)

10 Company Profiles
     10.1 Introduction
     10.2 ABBott Laboratories, Inc.
             10.2.1  Business Overview
             10.2.2  Financial Overview
             10.2.3  Product Offerings
             10.2.4  Recent Developments
     10.3 F.Hoffmann-La Roche Ltd.
     10.4 Thermofisher Scientific, Inc.
     10.5 Merck KGaA
     10.6 Agilent Technologies, Inc.
     10.7 Perkin Elmer, Inc.
     10.8 Danaher Corporation / Leica Biosystems Nussloch GmbH
     10.9 Exiqon A/S
     10.10 Biogenex Laboratories, Inc.
     10.11 Advanced Cell Diagnostics, Inc
     10.12 Bio Sb, Inc.

List of Tables (60 Tables)

Table 1 Global In Situ Hybridization Market, By Region/Country, 2016 (USD Million)
Table 2 Global Market Size, By Technique, 2014–2021 (USD Million)
Table 3 Global FISH Market Size, By Region, 2014–2021 (USD Million)
Table 4 North America: FISH Market Size, By Country, 2014–2021 (USD Million)
Table 5 Europe: FISH Market Size, By Country, 2014–2021 (USD Million)
Table 6 Global DNA-FISH Market Size, By Region, 2014–2021 (USD Million)
Table 7 North America: DNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 8 Europe: DNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 9 Global RNA-FISH Market Size, By Region, 2014–2021 (USD Million)
Table 10 North America: RNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 11 Europe: RNA-FISH Market Size, By Country, 2014–2021 (USD Million)
Table 12 Global CISH Market Size, By Region, 2014–2021 (USD Million)
Table 13 North America: CISH Market Size, By Country, 2014–2021 (USD Million)
Table 14 Europe: CISH Market Size, By Country, 2014–2021 (USD Million)
Table 15 Global In Situ Hybridization Market Size, By Application, 2014–2021 (USD Million)
Table 16 Global Market Size for Cancer Diagnosis, By Country/Region, 2014–2021 (USD Million)
Table 17 Global Market Size for Cytology, By Country/Region, 2014–2021 (USD Million)
Table 18 Global Market Size for Neuroscience, By Country/Region, 2014–2021 (USD Million)
Table 19 Global Market Size for Immunology, By Country/Region, 2014–2021 (USD Million)
Table 20 Global Market Size for Infectious Diseases, By Country/Region, 2014–2021 (USD Million)
Table 21 Global Market Size, By End User, 2014–2021 (USD Million)
Table 22 Global Market Size for Molecular Diagnostic Laboratories, By Region, 2014–2021 (USD Million)
Table 23 North America: Market Size for Molecular Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 24 Europe: Market Size for Molecular Diagnostic Laboratories, By Country, 2014–2021 (USD Million)
Table 25 Global In Situ Hybridization Market Size for Academic & Research Institutes, By Region, 2014–2021 (USD Million)
Table 26 North America: Market Size for Academic & Research Institutes, By Country, 2014 – 2021 (USD Million)
Table 27 Europe: Market Size for Academic & Research Institutes, By Country, 2014–2021 (USD Million)
Table 28 Global Market Size for Contract Research Organizations, By Region, 2014 – 2021 (USD Million)
Table 29 North America: Market Size for Contract Research Organizations, By Country, 2014 – 2021 (USD Million)
Table 30 Europe: Market Size for Contract Research Organizations, By Country, 2014–2021 (USD Million)
Table 31 Global Market Size for Pharmaceutical & Biotechnology Companies, By Region, 2014–2021 (USD Million)
Table 32 North America: Market Size for Pharmaceutical & Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 33 Europe: Market Size for Pharmaceutical & Biotechnology Companies, By Country, 2014–2021 (USD Million)
Table 34 Global Market Size, By Region, 2014–2021 (USD Million)
Table 35 North America: In Situ Hybridization Market Size, By Country, 2014–2021 (USD Million)
Table 36 North America: Market Size, By Technique, 2014–2021 (USD Million)
Table 37 North America: Market Size, By Application, 2014–2021 (USD Million)
Table 38 North America: Market Size, By End User, 2014–2021 (USD Million)
Table 39 U.S.: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 40 U.S.: Market Size, By Application, 2014–2021 (USD Million)
Table 41 U.S.: Market Size, By End User, 2014–2021 (USD Million)
Table 42 Canada: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 43 Canada: Market Size, By Application, 2014–2021 (USD Million)
Table 44 Canada: Market Size, By End User, 2014–2021 (USD Million)
Table 45 Europe: In Situ Hybridization Market Size, By Country, 2014–2021 (USD Million)
Table 46 Europe: Market Size, By Technique, 2014–2021 (USD Million)
Table 47 Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 48 Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 49 EU-5: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 50 EU-5: Market Size, By Application, 2014–2021 (USD Million)
Table 51 EU-5: Market Size, By End User, 2014–2021 (USD Million)
Table 52 Rest of Europe: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 53 Rest of Europe: Market Size, By Application, 2014–2021 (USD Million)
Table 54 Rest of Europe: Market Size, By End User, 2014–2021 (USD Million)
Table 55 Asia-Pacific: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 56 Asia-Pacific: Market Size, By Application, 2014–2021 (USD Million)
Table 57 Asia-Pacific: Market Size, By End User, 2014–2021 (USD Million)
Table 58 RoW: In Situ Hybridization Market Size, By Technique, 2014–2021 (USD Million)
Table 59 RoW: Market Size, By Application, 2014–2021 (USD Million)
Table 60 RoW: Market Size, By End User, 2014–2021 (USD Million)

List of Figures (26 Figure)

Figure 1 Market Size Estimation - USD Value
Figure 2 Market Sizing – (USD Value Analysis)
Figure 3 Competitive Assessment
Figure 4 Research Design
Figure 5 Data Triangulation
Figure 6 Global In Situ Hybridization Market, By Technique, 2016 (USD Million)
Figure 7 Global Market, By Application, 2016 (USD Million)
Figure 8 Global Market, By End User, 2016 (USD Million)
Figure 9 Market Overview
Figure 10 Global Market Segmentation, By Technique
Figure 11 The FISH Technique Segment is Expected to Dominate the Global Market in 2016
Figure 12 In Situ Hybridization Market Segmentation, By Application
Figure 13 Cancer Diagnosis Segment to Dominate the Market During the Forecast Period
Figure 14 Timeline of FDA Approvals for Key FISH-Based Companion Diagnostics in Oncology
Figure 15 Global Market Segmentation, By End User
Figure 16 Molecular Diagnostic Laboratories Dominate the Global Market, By End User (2016)
Figure 17 Market Share Analysis
Figure 18 Share of Key Strategies (2013–2016)
Figure 19 Agreements, Collaborations, and Partnerships (2013–2016)
Figure 20 Product Launches (2013–2016)
Figure 21 Expansions (2013–2016)
Figure 22 Acquisitions (2013–2016)
Figure 23 Other Strategies (2013–2016)
Figure 24 Route to Growth: Organic vs Inorganic Strategies
Figure 25  Organic Growth Strategies
Figure 26  Inorganic Growth Strategies

The in situ hybridization market is projected to reach USD 739.9 Million by 2021 from USD 557.1 Million in 2016, at a CAGR of 5.8% in the next five years (2016 to 2021). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

The global market is segmented on the basis of technique, application, and end user. By technique, the market is categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.

By application, the in situ hybridization market is categorized into cancer diagnosis, cytology, neuroscience, immunology, and infectious diseases. The cancer diagnosis segment is expected to command the largest share of the global market, by application in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This is attributed to factors such as rising prevalence of cancer, increasing adoption of FISH in diagnosis of cancer, and rising demand for FISH-based companion diagnostics for cancer.

On the basis of end users, the global market is segmented into molecular diagnostic laboratories, academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies. In 2016, the molecular diagnostic laboratories segment is estimated to account for the largest share of the global market, by end user. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to the availability of specialized skill sets in molecular diagnostic laboratories for ISH technique, rising prevalence of cancer coupled with genetic abnormalities, and increasing adoption of FISH in diagnosis of cancer and genetic abnormalities.

On the basis of region, this market is categorized into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to account for the largest share of the market in 2016. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of companion diagnostics is attributed to the development and launch of newer therapeutic agents. However, the Asia-Pacific region is expected to grow at the highest CAGR during the forecast period.  This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region.

The market is expected to be dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). Asia-Pacific is expected to grow at the highest rate during the forecast period.

Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.) are some of the key players in the in situ hybridization market worldwide.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst